4.30
0.20 (4.88%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | BioAge Labs, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 3.62% |
| % Held by Institutions | 70.68% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sofinnova Investments, Inc. | 30 Sep 2024 | 2,304,901 |
| Redpoint Management, Llc | 30 Sep 2024 | 383,255 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Morgan Stanley, 830.23%) | Buy |
| Median | 7.00 (62.79%) | |
| Low | 7.00 (Citigroup, 62.79%) | Hold |
| 7.00 (Jefferies, 62.79%) | Hold | |
| Average | 18.00 (318.61%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 11.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 09 Dec 2024 | 7.00 (62.79%) | Hold | 4.65 |
| 21 Oct 2024 | 45.00 (946.51%) | Buy | 25.83 | |
| Jefferies | 09 Dec 2024 | 7.00 (62.79%) | Hold | 4.65 |
| 21 Oct 2024 | 42.00 (876.74%) | Buy | 25.83 | |
| Morgan Stanley | 21 Oct 2024 | 40.00 (830.23%) | Buy | 25.83 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |